RxDoctor Payments Data

George Krakowski, MD

Cardiovascular Disease · Doylestown, PANPI 1205290848

Payments from drug & device makers

$18,388in general payments, 2019–2025

Across 51 payments — averaging $360.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer Healthcare LLC$16K
  • E.r. Squibb & Sons, L.L.C.$409
  • Takeda Pharmaceuticals U.S.A., Inc.$308
  • Seagen Inc.$250
  • Pfizer$159
  • Amgen$133
  • plus $893 from 12 others

What the payments were for

  • Consulting fees$16,23688%
  • Food & beverage$1,95611%
  • Education$1961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,388 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$214,395
Medicare patients
1,412
Services billed
3,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$199,434
EntrestoSacubitril/Valsartan42$52,658
JardianceEmpagliflozin30$34,231
XareltoRivaroxaban20$26,048
FarxigaDapagliflozin Propanediol17$20,483
Metoprolol Succinate186$3,205
Rosuvastatin Calcium130$2,326
Valsartan61$1,906
Dofetilide16$1,703
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$1,498
Atorvastatin Calcium112$1,498
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide30$1,454
Ezetimibe32$1,138
Carvedilol88$947
Furosemide110$683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$199,434161 claims
NovartisEntresto$87$52,65842 claims
Boehringer IngelheimJardiance$77$34,23130 claims
AstraZenecaFarxiga$29$20,48317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →